VX-661
|
|
|
- CAS-Nr.
- 1152311-62-0
- Englisch Name:
- VX-661
- Synonyma:
- tezacaftor(VX661);(R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-Methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxaMide;CS-956;VX-661;VX-661/VX661;VX661/Tezacaftor;VX-661 USP/EP/BP;VX 661; VX661;VX-661;VX 661;VX661;VX-661; TEZACAFTOR;Tezacaftor D4Q: What is
Tezacaftor D4 Q: What is the CAS Number of
Tezacaftor D4
- CBNumber:
- CB22632076
- Summenformel:
- C26H27F3N2O6
- Molgewicht:
- 520.5
- MOL-Datei:
- 1152311-62-0.mol
|
VX-661 Eigenschaften
- Siedepunkt:
- 610.8±55.0 °C(Predicted)
- Dichte
- 1.49±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C , stored under nitrogen
- Löslichkeit
- ≥21.8 mg/mL in DMSO; insoluble in EtOH; ≥24.3 mg/mL in H2O
- Aggregatzustand
- solid
- pka
- 13.99±0.20(Predicted)
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizität (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
|
VX-661 Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Tezacaftor (VX-661) is an oral medication for cystic fibrosis (CF) developed by Vertex Pharmaceuticals. In a combination therapy formulation called Symdeko (tezacaftor plus ivacaftor), it is approved in the U.S. and Canada for CF patients, ages 12 and older, who have two copies of the F508del mutation in the CFTR gene and one minimal function mutation. Symdeko is approved and marketed in the EU as Symkevi.Tezacaftor is not approved as a stand-alone treatment, but as part of a combination therapy.
Verwenden
Tezacaftor is used as a combination therapy with Ivacaftor for the treatment of patients with cystic fibrosis.
Definition
VX-661 is an investigational compound that promotes the maturation of delta F508 mutants of the cystic fibrosis transmembrane conductance regulator (CFTR). Delta F508 CFTR represents a class of CFTR mutation that is characterized by impaired processing of misfolded CFTR proteins and reduced accumulation of the protein at the cell surface. VX-661 is intended to facilitate trafficking of CFTR to the epithelial cell membrane. It may be combined with the CFTR potentiator ivacaftor (Item No. 15145) to stimulate both CFTR accumulation and opening at the apical epithelial surface.
VX-661 Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
VX-661 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 162)Lieferanten
1152311-62-0()Verwandte Suche:
- VX-661
- VX-661/VX661
- 1-(2,2-Difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1H-indol-5-yl]-cyclopropanecarboxamide
- Cyclopropanecarboxamide, 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1H-indol-5-yl]-
- 1-(2,2-Difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1H-indol-5-yl]-cyclopropanecarboxamide VX661
- (R)-1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-
- CS-956
- VX661/Tezacaftor
- VX 661; VX661;VX-661
- 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide
- VX 661;VX661;VX-661; TEZACAFTOR
- Tezacaftor D4Q: What is
Tezacaftor D4 Q: What is the CAS Number of
Tezacaftor D4
- VX-661 USP/EP/BP
- (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-Methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxaMide
- tezacaftor(VX661)
- inhibit,Tezacaftor,Inhibitor,VX-661,Cystic fibrosis transmembrane conductance regulator,Autophagy,VX 661,CFTR
- 1152311-62-0
- C26H27F3N2O6
- Inhibitors
- API
